U.S. Cancer Biopsy Market Size, Share | Report 2023-2032
The U.S. cancer biopsy market was estimated at USD 8.70 billion in 2022 and it is expected to surpass around USD 25.11 billion by 2032, poised to grow at a CAGR of 11.18% from 2023 to 2032.
Key Pointers
| Report Coverage | Details |
| Market Size in 2022 | USD 8.70 billion |
| Revenue Forecast by 2032 | USD 25.11 billion |
| Growth rate from 2023 to 2032 | CAGR of 11.18% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Companies Covered | BD (Becton, Dickinson and Company); IZI Medical Products; Johnson & Johnson Services, Inc.; Argon Medical; Spectra Medical Devices, Inc.; Medtronic; Boston Scientific Corporation; CONMED Corporation; INRAD, Inc.; Thermo Fisher Scientific, Inc. |
The U.S. cancer biopsy market is witnessing growth due to the factors such as advancements in quality & payment pertaining to genetic cancer diseases and the advent of liquid biopsies and their growing clinical implementation. Moreover, the increasing prevalence of cancer and the growing geriatric population is also likely to fuel the market growth. The COVID-19 outbreak has negatively impacted cancer treatment tourism across the globe. Due to the travel restrictions imposed by several countries, the treatment of many patients was interrupted abruptly. This may hinder the market growth of medical tourism for cancer treatment.
Cancer remains the leading cause of death across the globe. Thus, there is a growing need for advanced diagnostic tools designed for early detection. In recent years, precision oncology has emerged as a promising approach to management. With the evolution of the precision oncology field, companion diagnostic tools are increasingly being utilized to guide treatment decisions and select therapies based on a patient’s unique genomic profile. These tools facilitate the effective & safe use of corresponding therapeutic products. Till June 2021, more than 40 FDA-approved companion diagnostic assays for oncology indications are available in the market.
Advancements in diagnostic methods have created scope for their widespread clinical applications as well as translational research applications. Several initiatives have been undertaken to accelerate the utilization of various methods in translational research across academia and research industry. The Cancer Moonshot Blood Profiling Atlas is one such initiative that aims to accelerate the development of liquid biopsy tests for the management of cancer. This initiative focuses on collaborations between academia, government, and industries to boost test development.
Accurate detection of the progression of cancer is very important for the selection of an appropriate treatment regimen. Currently, available tests show false-positive results in some cases. Thus, supportive confirmatory tests are required to be performed, which increases the monetary burden on patients. Tests using tumor markers and specific biomarkers give results that are relatively more accurate. However, they are not available abundantly. As a result, the lack of highly sensitive tests is impeding market growth.
U.S. Cancer Biopsy Market Segmentations:
By Type
By Application
By Site (Organ)
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Cancer Biopsy Market
5.1. COVID-19 Landscape: U.S. Cancer Biopsy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. U.S. Cancer Biopsy Market, By Type
8.1. U.S. Cancer Biopsy Market, by Type, 2023-2032
8.1.1 Fine-needle Aspiration
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Core Biopsy
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Surgical Biopsy
8.1.3.1. Market Revenue and Forecast (2019-2032)
8.1.4. Skin Biopsy /Punch Biopsy
8.1.4.1. Market Revenue and Forecast (2019-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2019-2032)
Chapter 9. U.S. Cancer Biopsy Market, By Application
9.1. U.S. Cancer Biopsy Market, by Application, 2023-2032
9.1.1. Screening & Monitoring
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Diagnostics
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Investigational & Translational Research
9.1.3.1. Market Revenue and Forecast (2019-2032)
9.1.4. Pharma & Biopharma Discovery & Development
9.1.4.1. Market Revenue and Forecast (2019-2032)
Chapter 10. U.S. Cancer Biopsy Market, By Site (Organ)
10.1. U.S. Cancer Biopsy Market, by Site (Organ), 2023-2032
10.1.1. Liver
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Breast
10.1.2.1. Market Revenue and Forecast (2019-2032)
10.1.3. Thyroid
10.1.3.1. Market Revenue and Forecast (2019-2032)
10.1.4. Prostate Gland
10.1.4.1. Market Revenue and Forecast (2019-2032)
10.1.5. Uterus & Cervix
10.1.5.1. Market Revenue and Forecast (2019-2032)
10.1.6. Kidney
10.1.6.1. Market Revenue and Forecast (2019-2032)
10.1.7. Bladder
10.1.7.1. Market Revenue and Forecast (2019-2032)
10.1.8. Lungs
10.1.8.1. Market Revenue and Forecast (2019-2032)
10.1.9. Pancreas
10.1.9.1. Market Revenue and Forecast (2019-2032)
10.1.10. Others
10.1.10.1. Market Revenue and Forecast (2019-2032)
Chapter 11. U.S. Cancer Biopsy Market, Regional Estimates and Trend Forecast
11.1. U.S.
11.1.1. Market Revenue and Forecast, by Type (2019-2032)
11.1.2. Market Revenue and Forecast, by Application (2019-2032)
11.1.3. Market Revenue and Forecast, by Site (Organ) (2019-2032)
Chapter 12. Company Profiles
12.1. BD (Becton, Dickinson and Company)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. IZI Medical Products
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson & Johnson Services, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Argon Medical
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Spectra Medical Devices, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Medtronic
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Boston Scientific Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. CONMED Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. INRAD, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Thermo Fisher Scientific, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers